Effects of interventions on adiponectin and adiponectin receptors

Lee, Sewon; Kwak, Hyo-Bum; Sewon Lee; Hyo-Bum Kwak

doi:10.12965/jer.140104

J Exerc Rehabil > Volume 10(2);2014 > Article

Lee and Kwak: Effects of interventions on adiponectin and adiponectin receptors

Review Article

Journal of Exercise Rehabilitation 2014; 10(2): 60-68.

Published online: April 30, 2014

DOI: https://doi.org/10.12965/jer.140104

Effects of interventions on adiponectin and adiponectin receptors

Sewon Lee¹, Hyo-Bum Kwak^2,^*

¹Dalton Cardiovascular Research Center, University of Missouri-Columbia, MO, USA

²Department of Kinesiology, Inha University, Incheon, Korea

^*Corresponding author: Hyo-Bum Kwak, Department of Kinesiology, Inha University, 100 Inha-ro, Nam-gu, Incheon 402-751, Korea, Tel: +82-32-860-8183, Fax: +82-32-860-8188, Email: kwakhb@inha.ac.kr

Received April 16, 2014 Accepted April 21, 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Adiponectin secreted from adipose tissue binds to two distinct adiponectin receptors (AdipoR1 and AdipoR2) identified and exerts its anti-diabetic effects in insulin-sensitive organs including liver, skeletal muscle and adipose tissue as well as amelioration of vascular dysfunction in the various vasculatures. A number of experimental and clinical observations have demonstrated that circulating levels of adiponectin are markedly reduced in obesity, type 2 diabetes, hypertension, and coronary artery disease. Therapeutic interventions which can improve the action of adiponectin including elevation of circulating adiponectin concentration or up-regulation and/or activation of its receptors, could provide better understanding of strategies to ameliorate metabolic disorders and vascular disease. The focus of the present review is to summarize accumulating evidence showing the role of interventions such as pharmacological agents, exercise, and calorie restriction in the expression of adiponectin and adiponectin receptors.

Keywords: Pharmacological agents, Exercise, Calorie restriction, Adiponectin, Adiponectin receptors

INTRODUCTION

Nutrition imbalance and physical inactivity due to sedentary life style can lead to obesity, which is closely associated with an increased risk of metabolic syndrome (Booth et al., 2011; Booth et al., 2012). Metabolic disorders including insulin resistance and overt type 2 diabetes (T2D) are highly related to secondary cardiovascular complications such as hypertension, myocardial infarction, and stroke (Abate, 2000; Meshkani and Adeli, 2009). Adiponectin is one of adipokines secreted from adipose tissue and involved in various biological processes such as energy homeostasis, immune actions, and vascular homeostasis (Cheng et al., 2014; Hui et al., 2012). A number of clinical observations have demonstrated that circulating levels of adiponectin are markedly reduced in patients with obesity (Arita et al., 1999), T2D (Hotta et al., 2000), essential hypertension (Adamczak et al., 2003), and coronary artery disease (CAD) (Kumada et al., 2003; Nakamura et al., 2004). Based on above considerations, therapeutic interventions which can improve the action of adiponectin including elevation of circulating adiponectin concentration or up-regulation and/or activation of its receptors, could provide better understanding of strategies to ameliorate metabolic disorders and vascular disease. The focus of the present review is to summarize accumulating evidence showing the role of interventions such as pharmacological agents, exercise, calorie restriction (CR), and gastric bypass surgery (weight loss) in the expression of adiponectin and adiponectin receptors.

EFFECTS OF INTERVENTIONS ON ADIPONECTIN AND ADIPONECTIN RECEPTORS

Pharmacological/dietary interventions and lifestyle modifications such as exercise and CR to prevent and ameliorate cardiovascular disease and micro-vascular complications in T2D, have been shown to increase circulating levels of adiponectin in both experimental models and human studies (Simpson and Singh, 2008; Zhu et al., 2008). Up-regulation of endogenous adiponectin and its receptors by interventions might have multiple beneficial effects on metabolic and cardiovascular diseases.

Pharmacological and dietary intervention

Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor superfamily which functions as transcription factors regulating gene expression and play important roles in the regulation of cellular differentiation, development, and energy metabolism (Schoonjans et al., 1996). The three types of PPAR (α, γ, and β/δ) have been identified (Schoonjans et al., 1996). The PPAR-γ agonists, thiazolidinediones (TZDs) are widely used for anti-diabetic drugs that improve insulin sensitivity through enhancement of glucose disposal as well as reduction of gluconeogenesis in the target tissues of the body including skeletal muscle, liver, and adipose tissue (Furnsinn and Waldhausl, 2002; Kintscher and Law, 2005). A number of studies have shown that TZDs such as rosiglitazone and pioglitazone increased circulating levels of adiponectin in both human and experimental rodent models (Choi et al., 2005; Iwaki et al., 2003; Kubota et al., 2006; Pajvani et al., 2004). In addition to PPAR-γ, the PPAR-α agonist induced the increase in the circulating level of adiponectin associated with improvement in insulin sensitivity. For example, fenofibrate an agonist of nuclear receptor PPAR-α, increased serum levels of adiponectin in patients with primary hypertriglyceridemia (Koh et al., 2005). Previous studies have implicated that hypoadiponectinemia is associated with hypertension (Adamczak et al., 2003; Papadopoulos et al., 2009). Therefore, it is tempting to speculate whether anti-hypertensive drugs such as candesartan and losartan (angiotensin II receptor antagonists) increase adiponectin. These drugs, indeed, elevated circulating adiponectin without altering adiposity (Celik et al., 2006; Furuhashi et al., 2003; Koh et al., 2004; Koh et al., 2006). In addition, several other drugs for anti-diabetic (glimepiride) and anti-hypertension (nebivolol, β₁ receptor blocker) have been shown to enhance plasma adiponectin concentrations in human subjects (Celik et al., 2006; Nagasaka et al., 2003). However, it is unclear whether elevated adiponectin is associated with improved cardiovascular outcomes.

In addition to pharmacological agents, dietary fish oils (FO) and polyunsaturated fatty acids (PUFA) have been shown to increase mRNA expression of adiponectin in adipose tissue and circulating levels of adiponectin in several experimental models and human (Mostowik et al., 2013; Neschen et al., 2006; Rossi et al., 2005). Furthermore, Oolong tea, green tea extract and (-)-catechin increased plasma adiponectin in humans and rodent models (Cho et al., 2007; Li et al., 2006; Shimada et al., 2004). Table 1 summarized the effects of pharmacological agents and dietary intervention on the expression of adiponectin.

Exercise

It is well documented that exercise or regular physical activity has beneficial effects on metabolic and cardiovascular disease. Considering previous literatures, it is unclear whether exercise training (physical activity) increases adiponectin in circulation and its receptors in insulin-sensitive tissues such as adipose tissue, liver, and skeletal muscle. Complicating interpretation of the existing data is dependent on multiple factors including species, the pathological condition, types (endurance vs resistance exercise), intensity (low, moderate, and intense), and duration of exercise (acute vs chronic, short-term vs long-term), and sex. For example, in healthy, young subjects, it seemed that both acute and chronic aerobic exercise did not alter plasma level of adiponectin (Ferguson et al., 2004; Hulver et al., 2002; Jurimae et al., 2006; Punyadeera et al., 2005). However, chronic endurance training increased plasma adiponectin in obese adolescents (Balagopal et al., 2005), obese adults (Kondo et al., 2006), Caucasian subjects with impaired glucose tolerance (IGT) and T2D (Bluher et al., 2006; Oberbach et al., 2006). Furthermore, endurance training increased mRNA expression of adiponectin receptor (AdipoR) 1 and 2 in adipose tissue and skeletal muscle in normal glucose tolerance (NGT), IGT, and type 2 diabetic patients (Bluher et al., 2006; Bluher et al., 2007; Oberbach et al., 2006). On the other hand, some studies by several other groups have shown that aerobic exercise did not change adiponectin expression in obese subject (Polak et al., 2006), insulin resistant female subjects (Marcell et al., 2005), and patients with T2D (Boudou et al., 2003; Yokoyama et al., 2004). Interestingly, Fatouros et al. have demonstrated that only moderate-high intensity resistance training, not low intensity, increased plasma adiponectin in inactive subjects, suggesting that the intensity of exercise may be an important factor in the expression of adiponectin (Fatouros et al., 2005). Table 2 shows a summary of studies examining effects of exercise training on adiponectin and AdipoRs in both human and experimental models.

Calorie restriction, weight loss, and gastric bypass surgery

Calorie restriction (CR) refers to a dietary regimen low in calories without malnutrition and is known as an efficient lifestyle modification that delays the onset of metabolic and cardiovascular disease (Cava and Fontana, 2013). Weight loss and/or CR have been shown to improve insulin resistance, T2D, and cardiovascular dysfunction in both human and rodent models (Weiss and Fontana, 2011). In addition, sustained weight loss by gastric bypass surgery ameliorated cardiovascular dysfunction (Brethauer et al., 2011; Zhang et al., 2011). Although it is not clear whether beneficial effects of these interventions are mediated by adiponectin signaling pathways, a number of studies have shown that CR and/or weight loss by gastric bypass surgery increased circulating levels of adiponectin. For example, CR increased circulating adiponectin in normal (Fontana et al., 2010; Schulte et al., 2013) and obese subjects (Kobayashi et al., 2004; Oberhauser et al., 2012; Varady et al., 2010). However, some studies have shown that CR did not change plasma levels of adiponectin in patients with metabolic syndrome (Xydakis et al., 2004) and T2D (Plum et al., 2011). Interestingly, Varady et al. (2009) have implicated that circulating adiponectin concentration increased 20% in the 5–10% weight loss group, not less than 5% weight loss group, suggesting a minimum degree of weight loss are required to improve adipokine profile in severely obese women. On the other hand, Plum et al. suggested that Roux-en-Y gastric bypass surgery, not low calorie diet group, increased plasma adiponectin concentration in patients with T2D, although weight loss was comparable in both groups (Plum et al., 2011). This may suggest that Roux-en-Y gastric bypass surgery is more effective method than low calorie diet regimen in some kinds of obese diabetic patients. Because metabolic and cardiovascular diseases are multi-factorial phenomena, we need to consider the effect of other metabolic disorders such as dyslipidemia, hypercholesterolemia, and hypertension on the expression of adiponectin. Table 3 summarizes the effects of CR, weight loss and gastric bypass surgery on adiponectin.

CONCLUSIONS

There is no doubt that pharmacological agents and lifestyle modifications affect metabolic and cardiovascular disease. In regard to the expression of adiponectin and its receptors with these interventions, it remains unclear whether these interventions ameliorate metabolic and cardiovascular dysfunction through adiponectin and its receptors-mediated signaling pathways. Recent studies provide compelling evidence supporting the beneficial role of adiponectin in the metabolic and cardiovascular diseases. Although significant progress has made in understanding the molecular mechanisms that underlie the beneficial actions of adiponectin, it should be noted that large discrepancies exist among those studies based on experimental design including species, type of intervention, and the pathological condition. Further investigations in adiponectin signaling pathways will provide potential targets used for the therapeutic interventions in metabolic and cardiovascular disease.

Notes

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

This work was supported by Inha University Research Grant.

REFERENCES

Abate N. Obesity and cardiovascular disease. Pathogenetic role of the metabolic syndrome and therapeutic implications. J Diabetes Complications 2000;14:154–174.

Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003;16:72–75.

Anderlova K, Kremen J, Dolezalova R, Housova J, Haluzikova D, Kunesova M, Haluzik M. The influence of very-low-calorie-diet on serum leptin, soluble leptin receptor, adiponectin and resist in levels in obese women. Physiol Res 2006;55:277–283.

Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79–83.

Balagopal P, George D, Yarandi H, Funanage V, Bayne E. Reversal of obesity-related hypoadiponectinemia by lifestyle intervention: a controlled, randomized study in obese adolescents. J Clin Endocrinol Metab 2005;90:6192–6197.

Bluher M, Bullen JW, Lee JH, Kralisch S, Fasshauer M, Kloting N, Nie-bauer J, Schon MR, Williams CJ, Mantzoros CS. Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: associations with metabolic parameters and insulin resistance and regulation by physical training. J Clin Endocrinol Metab 2006;91:2310–2316.

Bluher M, Williams CJ, Kloting N, Hsi A, Ruschke K, Oberbach A, Fasshauer M, Berndt J, Schon MR, Wolk A, Stumvoll M, Mantzoros CS. Gene expression of adiponectin receptors in human visceral and subcutaneous adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical training. Diabetes Care 2007;30:3110–3115.

Bodles AM, Banga A, Rasouli N, Ono F, Kern PA, Owens RJ. Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. Am J Physiol Endocrinol Metab 2006;291:E1100–1105.

Booth FW, Laye MJ, Roberts MD. Lifetime sedentary living accelerates some aspects of secondary aging. J Appl Physiol 2011;111:1497–1504.

Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of chronic diseases. Compr Physiol 2012;2:1143–1211.

Boudou P, Sobngwi E, Mauvais-Jarvis F, Vexiau P, Gautier JF. Absence of exercise-induced variations in adiponectin levels despite decreased abdominal adiposity and improved insulin sensitivity in type 2 diabetic men. Eur J Endocrinol 2003;149:421–424.

Bradley RL, Jeon JY, Liu FF, Maratos-Flier E. Voluntary exercise improves insulin sensitivity and adipose tissue inflammation in diet-induced obese mice. Am J Physiol Endocrinol Metab 2008;295:E586–594.

Brethauer SA, Heneghan HM, Eldar S, Gatmaitan P, Huang H, Kashyap S, Gornik HL, Kirwan JP, Schauer PR. Early effects of gastric bypass on endothelial function, inflammation, and cardiovascular risk in obese patients. Surg Endosc 2011;25:2650–2659.

Cava E, Fontana L. Will calorie restriction work in humans? Aging (Albany NY) 2013;5:507–514.

Celik T, Iyisoy A, Kursaklioglu H, Kardesoglu E, Kilic S, Turhan H, Yilmaz MI, Ozcan O, Yaman H, Isik E, Fici F. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006;24:591–596.

Cerqueira FM, Brandizzi LI, Cunha FM, Laurindo FR, Kowaltowski AJ. Serum from calorie-restricted rats activates vascular cell eNOS through enhanced insulin signaling mediated by adiponectin. PLoS One 2012;7:e31155

Cheng KK, Lam KS, Wang B, Xu A. Signaling mechanisms underlying the insulin-sensitizing effects of adiponectin. Best Pract Res Clin Endocrinol Metab 2014;28:3–13.

Cho SY, Park PJ, Shin HJ, Kim YK, Shin DW, Shin ES, Lee HH, Lee BG, Baik JH, Lee TR. (-)-Catechin suppresses expression of Kruppel-like factor 7 and increases expression and secretion of adiponectin protein in 3T3-L1 cells. Am J Physiol Endocrinol Metab 2007;292:E1166–1172.

Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH, Choi KM. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun 2005;336:747–753.

Connolly BA, O’Connell DP, Lamon-Fava S, LeBlanc DF, Kuang YL, Schaefer EJ, Coppage AL, Benedict CR, Kiritsy CP, Bachovchin WW. The high-fat high-fructose hamster as an animal model for niacin’s biological activities in humans. Metabolism 2013;62:1840–1849.

Dai Y, Pang J, Gong H, Fan W, Zhang TM. Roles and tissue source of adiponectin involved in lifestyle modifications. J Gerontol A Biol Sci Med Sci 2013;68:117–128.

Dolinsky VW, Morton JS, Oka T, Robillard-Frayne I, Bagdan M, Lopaschuk GD, Des Rosiers C, Walsh K, Davidge ST, Dyck JR. Calorie restriction prevents hypertension and cardiac hypertrophy in the spontaneously hypertensive rat. Hypertension 2010;56:41221

Farias JM, Maggi RM, Tromm CB, Silva LA, Luciano TF, Marques SO, Lira FS, de Souza CT, Pinho RA. Exercise training performed simultaneously to a high-fat diet reduces the degree of insulin resistance and improves adipoR1-2/APPL1 protein levels in mice. Lipids Health Dis 2012;11:134

Fatouros IG, Tournis S, Leontsini D, Jamurtas AZ, Sxina M, Thomakos P, Manousaki M, Douroudos I, Taxildaris K, Mitrakou A. Leptin and adiponectin responses in overweight inactive elderly following resistance training and detraining are intensity related. J Clin Endocrinol Metab 2005;90:5970–5977.

Fenton JI, Nunez NP, Yakar S, Perkins SN, Hord NG, Hursting SD. Diet-induced adiposity alters the serum profile of inflammation in C57BL/6N mice as measured by antibody array. Diabetes Obes Metab 2009;11:343–354.

Ferguson MA, White LJ, McCoy S, Kim HW, Petty T, Wilsey J. Plasma adiponectin response to acute exercise in healthy subjects. Eur J Appl Physiol 2004;91:324–329.

Fontana L, Klein S, Holloszy JO. Effects of long-term calorie restriction and endurance exercise on glucose tolerance, insulin action, and adipokine production. Age (Dordr) 2010;32:97–108.

Furnsinn C, Waldhausl W. Thiazolidinediones: metabolic actions in vitro. Diabetologia 2002;45:1211–1223.

Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003;42:76–81.

Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595–1599.

Huang H, Iida KT, Sone H, Yokoo T, Yamada N, Ajisaka R. The effect of exercise training on adiponectin receptor expression in KKAy obese/diabetic mice. J Endocrinol 2006;189:643–653.

Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: an update. Br J Pharmacol 2012;165:574–590.

Hulver MW, Zheng D, Tanner CJ, Houmard JA, Kraus WE, Slentz CA, Sinha MK, Pories WJ, MacDonald KG, Dohm GL. Adiponectin is not altered with exercise training despite enhanced insulin action. Am J Physiol Endocrinol Metab 2002;283:E861–865.

Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003;52:1655–1663.

Jamurtas AZ, Theocharis V, Koukoulis G, Stakias N, Fatouros IG, Kouretas D, Koutedakis Y. The effects of acute exercise on serum adiponectin and resistin levels and their relation to insulin sensitivity in over-weight males. Eur J Appl Physiol 2006;97:122–126.

Jiang HY, Koike T, Li P, Wang ZH, Kawata Y, Oshida Y. Combined effects of short-term calorie restriction and exercise on insulin action in normal rats. Horm Metab Res 2010;42:950–954.

Jurimae J, Purge P, Jurimae T. Adiponectin is altered after maximal exercise in highly trained male rowers. Eur J Appl Physiol 2005;93:502–505.

Jurimae J, Purge P, Jurimae T. Adiponectin and stress hormone responses to maximal sculling after volume-extended training season in elite rowers. Metabolism 2006;55:13–19.

Kintscher U, Law RE. PPARgamma-mediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab 2005;288:E287–291.

Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Abe Y, Funahashi T, Matsuzawa Y. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004;94:e27–31.

Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005;28:1419–24.

Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Kang MH, Ahn TH, Choi IS, Shin EK. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004;110:3687–3692.

Koh KK, Quon MJ, Han SH, Chung WJ, Lee Y, Shin EK. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 2006;108:96–100.

Kondo T, Kobayashi I, Murakami M. Effect of exercise on circulating adipokine levels in obese young women. Endocr J 2006;53:189–195.

Kontogianni MD, Vlassopoulos A, Gatzieva A, Farmaki AE, Katsiougiannis S, Panagiotakos DB, Kalogeropoulos N, Skopouli FN. Flaxseed oil does not affect inflammatory markers and lipid profile compared to olive oil, in young, healthy, normal weight adults. Metabolism 2013;62:686–693.

Kubota N, Terauchi Y, Kubota T, Kumagai H, Itoh S, Satoh H, Yano W, Ogata H, Tokuyama K, Takamoto I, Mineyama T, Ishikawa M, Moroi M, Sugi K, Yamauchi T, Ueki K, Tobe K, Noda T, Nagai R, Kadowaki T. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem 2006;281:8748–8755.

Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y; Osaka C.A.D.S.G.C.a.d. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85–89.

Lee S, Park Y, Dellsperger KC, Zhang C. Exercise training improves endothelial function via adiponectin-dependent and independent pathways in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 2011;301:H306–314.

Li RW, Douglas TD, Maiyoh GK, Adeli K, Theriault AG. Green tea leaf extract improves lipid and glucose homeostasis in a fructose-fed insulin-resistant hamster model. J Ethnopharmacol 2006;104:24–31.

Marcell TJ, McAuley KA, Traustadottir T, Reaven PD. Exercise training is not associated with improved levels of C-reactive protein or adiponectin. Metabolism 2005;54:533–541.

Markofski MM, Carrillo AE, Timmerman KL, Jennings K, Coen PM, Pence BD, Flynn MG. Exercise training modifies ghrelin and adiponectin concentrations and is related to inflammation in older adults. J Gerontol A Biol Sci Med Sci 2013;10.1093/gerona/glt132.

Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 2009;42:1331–1346.

Mostowik M, Gajos G, Zalewski J, Nessler J, Undas A. Omega-3 polyun-saturated fatty acids increase plasma adiponectin to leptin ratio in stable coronary artery disease. Cardiovasc Drugs Ther 2013;27:289–295.

Nagasaka S, Taniguchi A, Aiso Y, Yatagai T, Nakamura T, Nakai Y, Fukushima M, Kuroe A, Ishibashi S. Effect of glimepiride on serum adiponectin level in subjects with type 2 diabetes. Diabetes Care 2003;26:2215–2226.

Nakamura Y, Shimada K, Fukuda D, Shimada Y, Ehara S, Hirose M, Kataoka T, Kamimori K, Shimodozono S, Kobayashi Y, Yoshiyama M, Takeuchi K, Yoshikawa J. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 2004;90:528–533.

Neschen S, Morino K, Rossbacher JC, Pongratz RL, Cline GW, Sono S, Gillum M, Shulman GI. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes 2006;55:924–928.

O’Leary VB, Jorett AE, Marchetti CM, Gonzalez F, Phillips SA, Ciaraldi TP, Kirwan JP. Enhanced adiponectin multimer ratio and skeletal muscle adiponectin receptor expression following exercise training and diet in older insulin-resistant adults. Am J Physiol Endocrinol Metab 2007;293:E421–427.

Oberbach A, Tonjes A, Kloting N, Fasshauer M, Kratzsch J, Busse MW, Paschke R, Stumvoll M, Bluher M. Effect of a 4 week physical training program on plasma concentrations of inflammatory markers in patients with abnormal glucose tolerance. Eur J Endocrinol 2006;154:577–585.

Oberhauser F, Schulte DM, Faust M, Gudelhofer H, Hahn M, Muller N, Neumann K, Krone W, Laudes M. Weight loss due to a very low calorie diet differentially affects insulin sensitivity and interleukin-6 serum levels in nondiabetic obese human subjects. Horm Metab Res 2012;44:465–470.

Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004;279:12152–12162.

Papadopoulos DP, Perrea D, Thomopoulos C, Sanidas E, Daskalaki M, Papazachou U, Votteas V, Makris T. Masked hypertension and atherogenesis: the impact on adiponectin and resistin plasma levels. J Clin Hypertens (Greenwich) 2009;11:61–65.

Plum L, Ahmed L, Febres G, Bessler M, Inabnet W, Kunreuther E, McMahon DJ, Korner J. Comparison of glucostatic parameters after hypocaloric diet or bariatric surgery and equivalent weight loss. Obesity (Silver Spring) 2011;19:2149–2157.

Polak J, Klimcakova E, Moro C, Viguerie N, Berlan M, Hejnova J, Rich-terova B, Kraus I, Langin D, Stich V. Effect of aerobic training on plasma levels and subcutaneous abdominal adipose tissue gene expression of adiponectin, leptin, interleukin 6, and tumor necrosis factor alpha in obese women. Metabolism 2006;55:1375–1381.

Punyadeera C, Zorenc AH, Koopman R, McAinch AJ, Smit E, Manders R, Keizer HA, Cameron-Smith D, van Loon LJ. The effects of exercise and adipose tissue lipolysis on plasma adiponectin concentration and adiponectin receptor expression in human skeletal muscle. Eur J Endocrinol 2005;152:427–436.

Rossi AS, Lombardo YB, Lacorte JM, Chicco AG, Rouault C, Slama G, Rizkalla SW. Dietary fish oil positively regulates plasma leptin and adiponectin levels in sucrose-fed, insulin-resistant rats. Am J Physiol Regul Integr Comp Physiol 2005;289:R486–494.

Rossmeislova L, Malisova L, Kracmerova J, Tencerova M, Kovacova Z, Koc M, Siklova-Vitkova M, Viquerie N, Langin D, Stich V. Weight loss improves the adipogenic capacity of human preadipocytes and modulates their secretory profile. Diabetes 2013;62:1990–1995.

Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37:907–925.

Schulte DM, Hahn M, Oberhauser F, Malchau G, Schubert M, Heppner C, Muller N, Gudelhofer H, Faust M, Krone W, Laudes M. Caloric restriction increases serum testosterone concentrations in obese male subjects by two distinct mechanisms. Horm Metab Res 2013;10.1055/s-0033-1358678.

Shimada K, Kawarabayashi T, Tanaka A, Fukuda D, Nakamura Y, Yoshiyama M, Takeuchi K, Sawaki T, Hosoda K, Yoshikawa J. Oolong tea increases plasma adiponectin levels and low-density lipoprotein particle size in patients with coronary artery disease. Diabetes Res Clin Pract 2004;65:227–234.

Simpson KA, Singh MA. Effects of exercise on adiponectin: a systematic review. Obesity (Silver Spring) 2008;16:241–256.

Varady KA, Allister CA, Roohk DJ, Hellerstein MK. Improvements in body fat distribution and circulating adiponectin by alternate-day fasting versus calorie restriction. J Nutr Biochem 2010;21:188–195.

Varady KA, Tussing L, Bhutani S, Braunschweig CL. Degree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women. Metabolism 2009;58:1096–1101.

Wang Z, Masternak MM, Al-Regaiey KA, Bartke A. Adipocytokines and the regulation of lipid metabolism in growth hormone transgenic and calorie-restricted mice. Endocrinology 2007;148:2845–2853.

Weiss EP, Fontana L. Caloric restriction: powerful protection for the aging heart and vasculature. Am J Physiol Heart Circ Physiol 2011;301:H1205–1219.

Wheatley KE, Nogueira LM, Perkins SN, Hursting SD. Differential effects of calorie restriction and exercise on the adipose transcriptome in diet-induced obese mice. J Obes 2011;2011:265417

Wolfe BE, Jimerson DC, Orlova C, Mantzoros CS. Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers. Clin Endocrinol (Oxf) 2004;61:332–338.

Xydakis AM, Case CC, Jones PH, Hoogeveen RC, Liu MY, Smith EO, Nelson KW, Ballantyne CM. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab 2004;89:2697–2703.

Yatagai T, Nishida Y, Nagasaka S, Nakamura T, Tokuyama K, Shindo M, Tanaka H, Ishibashi S. Relationship between exercise training-induced increase in insulin sensitivity and adiponectinemia in healthy men. Endocr J 2003;50:233–238.

Yokoyama H, Emoto M, Araki T, Fujiwara S, Motoyama K, Morioka T, Koyama H, Shoji T, Okuno Y, Nishizawa Y. Effect of aerobic exercise on plasma adiponectin levels and insulin resistance in type 2 diabetes. Diabetes Care 2004;27:1756–1768.

Zhang H, Wang Y, Zhang J, Potter BJ, Sowers JR, Zhang C. Bariatric surgery reduces visceral adipose inflammation and improves endothelial function in type 2 diabetic mice. Arterioscler Thromb Vasc Biol 2011;31:2063–2069.

Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 2008;114:361–374.

Table 1.

Effects of pharmacological agents and dietary intervention on adiponectin

Subject or animal	Sex	Pharmacological agents	Duration	Methods for intake	Tissues	Methods	Conclusions	References
Non-diabetic patients	Female	-Pioglitazone (1–3 μM)	24 h	Cell culture	Subcutaneous fat (Biopsy)	PCR WB	= APN ↑ HMW APN	Bodles et al., 2006
Normal volunteers	Male	-Rosiglitazone (4 mg twice/daily)	2 wk	Oral intake	Serum sedimentation	Velocity	↑ Total APN ↑ HMW APN	Pajvani et al., 2004
Healthy normal weight subjects	Both	-Flaxseed oil (15 mL/day) -Olive oil (15 mL/day)	6 wk	Oral intake	Plasma	ELISA	= APN = APN	Kontogianni et al., 2013
Patients with primary hypertriglyceridemia	Both	-Fenofibrate (200 mg daily)	8 wk	Oral intake	Serum	ELISA	↑ APN	Koh et al., 2005
Patients with hypercholes terolemic hypertension	Both	-Simvastatin (20 mg) +Losartan (100 mg) -Losartan only (100 mg/daily)	2 mo	Oral intake	Plasma	ELISA	↑ APN ↑ APN	Koh et al., 2004
Patients with essential hypertension	Both	-Temocapril (4 mg/daily) -Candesartan (8 mg/daily)	2 wk	Oral intake	Serum	ELISA	↑ APN ↑ APN	Furuhashi et al., 2003
Patients with mild to moderate hypertension	Both	-Candesartan (16 mg/daily)	2 mo	Oral intake	Plasma	ELISA	↑ APN	Koh et al., 2006
Patients with hypertension	Both	-Nebivolol (5 mg/daily) -Metoprolol (100 mg/daily)	6 mo	Oral intake	Plasma	ELISA	↑ APN = APN	Celik et al., 2006
Patients with T2D	Both	-Glimepiride (1.9 mg/daily) -Metformin (750 mg/daily)	3 mo	Oral intake	Serum	ELISA	↑ APN ↑ APN	Nagasaka et al., 2003
Patients with CAD	Both	-Oolong tea (1,000 mL) vs. water	1 mo	Oral intake	Plasma	ELISA	↑ APN	Shimada et al., 2004
Patients with CAD	Both	-Omega-3 PUFA	4 wk	Oral intake	Plasma	ELISA	↑ APN	Mostowik et al., 2013
Rats (OLETF)	Male	-Rosiglitazone (2 mg/kg/day) -Fenofibrate (100 mg/kg/day)	40 wk	In food	Serum	ELISA	↑ APN = APN	Choi et al., 2005
Rats (Wistar)	Male	-Sucrose Rich Diet -Sucrose Rich Diet (7 mo)+FO Diet (2 mo)	9 mo	In food	Plasma	ELISA	↓ APN ↑ APN	Rossi et al., 2005
Hamsters (Golden Syrian)	Male	-Green tea extract (low dose 150 mg/kg) -Green tea extract (high dose 300 mg/kg)	4 wk	Oral gavage	Plasma	ELISA	↑ APN ↑ APN	Li et al., 2006
Hamsters (Golden Syrian)	Male	-Niacin (1,200 mg/kg)	18 days	Oral gavage	AT	PCR	↑ APN	Connolly et al., 2013
Mice (ob/ob)	Male	-Pioglitazone (10 mg/kg) -Pioglitazone (30 mg/kg)	2 wk	Oral gavage	Serum	ELISA	↑ APN ↑↑ APN	Kubota et al., 2006
Mice (db/db)	Male	-Troglitazone (0.2%) -Pioglitazone (0.01%)	2 wk	In food	Subcutaneous AT Serum	PCR WB	↑ APN ↑ APN	Iwaki et al., 2003
Mice (db/db)	Male	-Rosiglitazone (10 mg/kg)	11 days	Oral gavage	Serum sedimentation	Velocity	= Total APN ↑ HMW APN	Pajvani et al., 2004
Mice (129 Sv)	Male	−27% Fish oil	8 or 15 days	In food	Plasma Epididymal AT Subcutaneous AT	ELISA PCR PCR	↑ APN ↑ APN = APN	Neschen et al., 2006
Mice (3T3-L1 adipocytes)	-	(-)-catechin (50 μM) (-)-catechin (5–100 μM) (-)-catechin (50 μM)	24 h	Cell culture	Adipocytes	WB ELISA PCR	↑ APN ↑ APN ↑ APN	Cho et al., 2007

APN, adiponectin; AT, adipose tissue; CAD, coronary artery disease; db/db, leptin receptor mutated mouse; ELISA, enzyme linked immunosorbent assay; FO, fish oil; HMW, high molecular weight; OLETF rat, Otsuka Long-Evans Tokushima fatty rat; ob/ob, leptin deficient mouse; PCR, polymerase chain reaction; PUFA, polyunsaturated fatty acid; T2D, type 2 diabetes; WB, western blotting; ↑, increase; ↓, decrease; =, no change.

Table 2.

Effects of exercise on adiponectin and adiponectin receptors

Subject or animal	Sex	Type of exercise	Duration	Tissues	Methods	Conclusions	References
Healthy subjects	Both	Cycle ergometry training	60 min (Acute)	Plasma	ELISA	= APN	Ferguson et al., 2004
Healthy subjects	Both	Aerobic training	6 mo (4 days/wk)	Plasma	ELISA	= APN	Hulver et al., 2002
Healthy non-obese subjects	Male	Ergometer training	6 wk (5 days/wk)	Serum	ELISA	↓ APN (At 16 h after the last training session)	Yatagai et al., 2003
Young subjects	Male	Cycle ergometer	2 h (Acute)	Plasma	ELISA	= APN	Punyadeera et al., 2005
Highly-trained young rowers	Male	Rowing ergometer	Maximal 6,000 m test (Acute)	Plasma	ELISA	↑ APN (After 30 min of recovery)	Jurimae et al., 2005
Highly-trained young rowers	Male	Training for rowers	6 mo	Plasma	ELISA	= APN	Jurimae et al., 2006
Inactive subjects	Male	Resistance training (low, moderate, high intensity)	6 mo (3 days/wk)	Plasma	ELISA	= APN (low intensity) ↑ APN (moderate) ↑ APN (high)	Fatouros et al., 2005
Young overweight subjects	Male	Cycle ergometer	45 min (Acute)	Plasma	ELISA	= APN (Post 24, 48 h)	Jamurtas et al., 2006
Obese subjects	Both	Aerobic exercise + hypo-caloric (ExHypo) or eucoloric (ExEu) diet	12 wk (5 days/wk)	Serum Skeletal muscle	ELISA PCR	↑ HMW/Total APN ↑ AdipoR1 and 2	O’Leary et al., 2007
Obese subjects	Female	Aerobic exercise (Bicycle ergometer)	12 wk (5 days/wk)	Plasma SCAAT (biopsy)	ELISA PCR	= APN = APN	Polak et al., 2006
Obese subjects	Female	Endurance training	7 mo (4–5 days/wk)	Plasma	ELISA	↑ APN	Kondo et al., 2006
Obese adolescents	Both	Aerobic activities	3 mo (3 days/wk)	Plasma	ELISA	↑ APN	Balagopal et al., 2005
Middle-aged subjects with insulin resistance	Both	Aerobic exercise (moderate to intense)	16 wk (5 days/wk)	Plasma	ELISA	= APN	Marcell et al., 2005
Caucasian subjects with NGT, IGT, and T2D	Both	Physical training	4 wk (3 days/wk)	Serum Skeletal muscle	ELISA PCR	↑ APN ↑ AdipoR1 and 2	Bluher et al., 2006
Caucasian subjects with NGT, IGT, and T2D	Both	Physical training	4wk (3 days/wk)	Subcutaneous AT Skeletal muscle	PCR PCR	↑ AdipoR1 and 2 ↑ AdipoR1 and 2	Bluher et al., 2007
Caucasian subjects with NGT, IGT, and T2D	Both	Physical training program (Aerobic + Power training)	4 wk (3 days/wk)	Plasma	ELISA	= APN in NGT ↑ APN in IGT ↑ APN in T2D	Oberbach et al., 2006
Caucasian subjects with NGT, IGT, and T2D	Both	Physical training (Aerobic exercise)	4 wk (3 days/wk)	Plasma Skeletal muscle	ELISA PCR	↑ APN in NGT, IGT and T2D ↑ AdipoR1 and 2 in NGT, IGT, and T2D	Bluher et al., 2006
Patients with T2D	Both	Aerobic exercise (walking and bicycle ergometer)	3 wk (5 days/wk)	Plasma	ELISA	= APN	Yokoyama et al., 2004
Middle-aged subjects with T2D	Male	Endurance training	8 wk (3 days/wk)	Plasma	ELISA	= APN	Boudou et al., 2003
Older, healthy subjects	Both	Aerobic and resistance exercise training	12 wk (3 days/wk)	Serum	ELISA	↑ APN	Markofski et al., 2013
Rats (SD)	Male	Endurance training	6 mo (5 days/wk)	Serum Skeletal muscle Adipose Skeletal muscle Adipose	ELISA PCR PCR WB WB	↑ APN ↑ APN = APN ↑ APN ↑ APN	Dai et al., 2013
Mice (Swiss)	Male	Swimming exercise	12 wk (5 days/wk)	Adipose Liver Skeletal muscle	WB	↑ AdipoR1 ↑ AdipoR1 ↑ AdipoR1	Farias et al., 2012
Mice (db/db)	Male	Endurance training	10 wk (5 days/wk)	Serum	ELISA	↑ APN	Lee et al., 2011
Mice (KKAy)	Male	Endurance training	8 wk (5 days/wk)	Skeletal muscle Skeletal muscle Liver Liver White adipose White adipose	PCR	↑ AdipoR1 = AdipoR2 ↑ AdipoR1 ↓ AdipoR1 = AdipoR1 = AdipoR1	Huang et al., 2006
Mice (C57BL/6)	Male	Voluntary wheel running	6 wk	Plasma	ELISA	= APN	Bradley et al., 2008

AdipoR, adiponectin receptor; APN, adiponectin; AT, adipose tissue; SCAAT, subcutaneous abdominal adipose tissue; db/db, leptin receptor mutated mouse; ELISA, enzyme linked immunosorbent assay; HMW, high molecular weight; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; PCR, polymerase chain reaction; SD, Sprague Dawley; T2D, type 2 diabetes; WB, western blotting; ↑, increase; ↓, decrease; =, no change.

Table 3.

Effects of calorie restriction (CR), weight loss, and gastric bypass surgery on adiponectin

Subject or animal	Sex	Type of treatment	Duration	Tissues	Methods	Conclusions	References
Normal subjects	Both	CR	≤ 7 yr	Serum	ELISA	↑ APN	Fontana et al., 2010
Normal weight subjects	Female	CR (1,000–1,200 kcal/day)	4 wk	Plasma	ELISA	↓ APN	Wolfe et al., 2004
Caucasian subjects	Male	CR (low calorie diet, 800 kcal/day)	12 wk	Serum	ELISA	↑ APN	Schulte et al., 2013
Obese subjects	Both	CR program	3 mo	Plasma	ELISA	↑ HMW APN ↓ hexamer APN ↓ trimer APN	Kobayashi et al., 2004
Obese subjects	Female	CR (↓ 600 kcal/day)	5–6 mo	Adipose Adipose Plasma Adipose Adipose Adipose	PCR ELISA ELISA WB WB WB	↑ APN ↑ APN = Total APN ↑ HMW APN = MMW APN ↓ LMW APN	Rossmeislova et al., 2013
Obese subjects	Both	CR (weight loss, very low caloric diet)	12 wk	Serum	ELISA	↑ APN	Oberhauser et al., 2012
Obese subjects	Female	CR (very low calorie diet)	3 wk	Serum	ELISA	= APN	Anderlova et al., 2006
Severely obese subjects	Female	CR (low-calorie diet, less than 5% weight loss or 5–10% weight loss)	3 wk	Plasma	ELISA	= APN (less than 5%) ↑ APN (5–10% weight loss)	Varady et al., 2009
Obese subjects with metabolic syndrome	Both	CR (very low-calorie diet)	12 mo	Plasma	ELISA	= APN	Xydakis et al., 2004
Patients with T2D	Both	Low calorie diet Roux-en-Y gastric bypass	3 mo	Plasma	ELISA	= APN ↑ APN	Plum et al., 2011
Rats (F344/NSIc)	Male	CR	4 wk	Plasma	ELISA	= HMW APN	Plum et al., 2011
Rats (SD)	Male	CR (40%)	6 mo	Serum Skeletal muscle Adipose Skeletal muscle Adipose	ELISA PCR PCR WB WB	↑ APN ↑ APN ↑ APN ↑ APN ↑ APN	Dai et al., 2013
Rats (SD)	Male	CR (40%)	26 wk	Serum	ELISA	↑ APN	Cerqueira et al., 2012
Rats (SHRs)	Male	CR	5 wk	Plasma	ELISA	↑ APN	Cerqueira et al., 2012
Mice (C57BL/6)	Female	CR	8 wk	Serum	ELISA	↑ APN	Wheatley et al., 2011
Mice (C57BL/6N)	Female	CR (30% caloric-restricted diet)	10 wk	Serum	ELISA	↑ APN	Fenton et al., 2009
Mice (C57BL/6J)	Female	CR Alternate-day fasting	4 wk	Plasma	ELISA	↑ APN ↑ APN	Varady et al., 2010
Mice (C57BL/6)	Male	CR	8 wk	Plasma	ELISA	↑ APN	Wang et al., 2007

APN, adiponectin; CR, calorie restriction; ELISA, enzyme linked immunosorbent assay; HMW, high molecular weight; LMW, low molecular weight; MMW, medium molecular weight; PCR, polymerase chain reaction; SD, Sprague Dawley; T2D, type 2 diabetes; SHRs, spontaneously hypertensive rats; WB, western blotting; ↑, increase; ↓, decrease; =, no change.